Black Diamond Therapeutics, Inc. (BDTX)
Nasdaq: BDTX · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2017
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Mar 16, 2026 | Mar 6, 2025 | Mar 12, 2024 | Mar 9, 2023 | Mar 17, 2022 | Mar 25, 2021 | Mar 24, 2020 | · |
| Revenue | 70,000 | 0 | · | · | · | 0 | 0 | 0 |
| Research and development | 33,558 | 51,312 | 59,350 | 64,437 | 96,829 | 48,209 | 21,753 | 6,950 |
| General and administrative | 16,572 | 27,469 | 27,110 | 28,391 | 30,043 | 21,361 | 7,579 | 1,954 |
| Total operating expenses | 57,478 | 78,781 | 86,460 | 92,828 | 126,872 | 69,570 | 29,332 | 8,904 |
| Operating income | 12,522 | -78,781 | -86,460 | -92,828 | -126,872 | -69,570 | -29,332 | -8,904 |
| Interest expense | · | · | · | · | 0 | 1 | 0 | · |
| Interest and investment income | 4,061 | 2,182 | 1,924 | 2,031 | 3,464 | 4,041 | 461 | 4 |
| Share of profit of equity-method investments | · | · | 0 | -2,250 | 0 | · | · | · |
| Other income (expense), net | 5,784 | 6,923 | 2,094 | -354 | -2,188 | -1,724 | 6 | -16 |
| Total non-operating income (expense) | 9,845 | 9,105 | 4,018 | 3,909 | 1,276 | 2,316 | -5,926 | -27 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 22,367 | -69,676 | -82,442 | -91,169 | -125,596 | -67,254 | -35,258 | -8,931 |
| Earnings per share, basic | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | · | · |
| Earnings per share, diluted | 0.39 | -1.27 | -1.88 | -2.52 | -3.47 | -2.05 | · | · |
| Earnings per share, basic and diluted | · | · | · | · | · | -2.05 | -16.99 | -4.42 |
| Weighted average shares, basic | 56,868,111 | 55,028,371 | 43,954,649 | 36,325,586 | 36,189,002 | 32,907,100 | · | · |
| Weighted average shares, diluted | 57,562,746 | 55,028,371 | 43,954,649 | 36,325,586 | 36,189,002 | 32,907,100 | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | · | 32,907,100 | 2,075,753 | 2,018,623 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNonoperatingShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted